Panel urges FDA to remove boxed warning on women’s hormone therapy
Regulatory NewsJoanne S. Eglovitch
Advertising, Promotion and LabelingAdvisory committeesHealth Authority meeting and communication strategyPharmaceuticalsPublic healthRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)